BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22172840)

  • 1. Association between urothelial carcinoma after kidney transplantation and aristolochic acid exposure: the potential role of aristolochic acid in HRas and TP53 gene mutations.
    Xiao J; Zhu X; Hao GY; Zhu YC; Hou HJ; Zhang J; Ma LL; Tian Y; Zhang YH
    Transplant Proc; 2011 Dec; 43(10):3751-4. PubMed ID: 22172840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 mutations in p53-negative dysplastic urothelial cells from Belgian AAN patients: New evidence for aristolochic acid-induced molecular pathogenesis and carcinogenesis.
    Aydin S; Ambroise J; Cosyns JP; Gala JL
    Mutat Res Genet Toxicol Environ Mutagen; 2017 Jun; 818():17-26. PubMed ID: 28477877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes.
    Chen CH; Dickman KG; Huang CY; Moriya M; Shun CT; Tai HC; Huang KH; Wang SM; Lee YJ; Grollman AP; Pu YS
    Int J Cancer; 2013 Jul; 133(1):14-20. PubMed ID: 23292929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid.
    Jelaković B; Karanović S; Vuković-Lela I; Miller F; Edwards KL; Nikolić J; Tomić K; Slade N; Brdar B; Turesky RJ; Stipančić Ž; Dittrich D; Grollman AP; Dickman KG
    Kidney Int; 2012 Mar; 81(6):559-67. PubMed ID: 22071594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid.
    Hollstein M; Moriya M; Grollman AP; Olivier M
    Mutat Res; 2013; 753(1):41-49. PubMed ID: 23422071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unambiguous detection of multiple TP53 gene mutations in AAN-associated urothelial cancer in Belgium using laser capture microdissection.
    Aydin S; Dekairelle AF; Ambroise J; Durant JF; Heusterspreute M; Guiot Y; Cosyns JP; Gala JL
    PLoS One; 2014; 9(9):e106301. PubMed ID: 25184754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De novo urothelial carcinoma in kidney transplant patients with end-stage aristolochic acid nephropathy in China.
    Yuan M; Shi YB; Li ZH; Xia M; Ji GZ; Xu GX; Han Y
    Transplant Proc; 2009 Jun; 41(5):1619-23. PubMed ID: 19545692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequence-specific detection of aristolochic acid-DNA adducts in the human p53 gene by terminal transferase-dependent PCR.
    Arlt VM; Schmeiser HH; Pfeifer GP
    Carcinogenesis; 2001 Jan; 22(1):133-40. PubMed ID: 11159751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aristolochic acid-associated urothelial cancer in Taiwan.
    Chen CH; Dickman KG; Moriya M; Zavadil J; Sidorenko VS; Edwards KL; Gnatenko DV; Wu L; Turesky RJ; Wu XR; Pu YS; Grollman AP
    Proc Natl Acad Sci U S A; 2012 May; 109(21):8241-6. PubMed ID: 22493262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma.
    Lu H; Liang Y; Guan B; Shi Y; Gong Y; Li J; Kong W; Liu J; Fang D; Liu L; He Q; Shakeel M; Li X; Zhou L; Ci W
    Theranostics; 2020; 10(10):4323-4333. PubMed ID: 32292497
    [No Abstract]   [Full Text] [Related]  

  • 11. Distinguishing characteristics of urothelial carcinoma in kidney transplant recipients between China and Western countries.
    Liu GM; Fang Q; Ma HS; Sun G; Wang XC
    Transplant Proc; 2013; 45(6):2197-202. PubMed ID: 23747184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool.
    Poon SL; Pang ST; McPherson JR; Yu W; Huang KK; Guan P; Weng WH; Siew EY; Liu Y; Heng HL; Chong SC; Gan A; Tay ST; Lim WK; Cutcutache I; Huang D; Ler LD; Nairismägi ML; Lee MH; Chang YH; Yu KJ; Chan-On W; Li BK; Yuan YF; Qian CN; Ng KF; Wu CF; Hsu CL; Bunte RM; Stratton MR; Futreal PA; Sung WK; Chuang CK; Ong CK; Rozen SG; Tan P; Teh BT
    Sci Transl Med; 2013 Aug; 5(197):197ra101. PubMed ID: 23926199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Outcome of Kidney Recipients Transplanted for Aristolochic Acid Nephropathy.
    Kanaan N; Hassoun Z; Raggi C; Jadoul M; Mourad M; De Meyer M; Aydin S; Schmeiser HH; Cosyns JP; Goffin E
    Transplantation; 2016 Feb; 100(2):416-21. PubMed ID: 26457602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing.
    Hoang ML; Chen CH; Sidorenko VS; He J; Dickman KG; Yun BH; Moriya M; Niknafs N; Douville C; Karchin R; Turesky RJ; Pu YS; Vogelstein B; Papadopoulos N; Grollman AP; Kinzler KW; Rosenquist TA
    Sci Transl Med; 2013 Aug; 5(197):197ra102. PubMed ID: 23926200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward clinical understanding of aristolochic acid upper-tract urothelial carcinoma.
    Boot A; Jiang N; Rozen SG
    Theranostics; 2020; 10(12):5578-5580. PubMed ID: 32373232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours.
    Nedelko T; Arlt VM; Phillips DH; Hollstein M
    Int J Cancer; 2009 Feb; 124(4):987-90. PubMed ID: 19030178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential microRNA expression in aristolochic acid-induced upper urothelial tract cancers ex vivo.
    Tao L; Zeng Y; Wang J; Liu Z; Shen B; Ge J; Liu Y; Guo Y; Qiu J
    Mol Med Rep; 2015 Nov; 12(5):6533-46. PubMed ID: 26397152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De novo urothelial carcinoma in kidney transplantation patients with end-stage aristolochic acid nephropathy in China.
    Li HZ; Xia M; Han Y; Xu XG; Zhang YS
    Urol Int; 2009; 83(2):200-5. PubMed ID: 19752617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aristolochic acid and the etiology of endemic (Balkan) nephropathy.
    Grollman AP; Shibutani S; Moriya M; Miller F; Wu L; Moll U; Suzuki N; Fernandes A; Rosenquist T; Medverec Z; Jakovina K; Brdar B; Slade N; Turesky RJ; Goodenough AK; Rieger R; Vukelić M; Jelaković B
    Proc Natl Acad Sci U S A; 2007 Jul; 104(29):12129-34. PubMed ID: 17620607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease.
    Grollman AP
    Environ Mol Mutagen; 2013 Jan; 54(1):1-7. PubMed ID: 23238808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.